CDMOs Nephron and Canton each raise hundreds of millions in financing
Nephron Pharmaceuticals and Canton Biologics recently announced capital raises totaling hundreds of millions of dollars, joining the growing market for contract and development manufacturing companies.
South Carolina-based Nephron said Friday that it raised $350 million for “future growth.” Nephron develops and produces generic inhalation solutions and suspension products as well as operates an outsourcing facility that makes products like pre-filled syringes and IV bags for hospitals that aim to help mitigate drug shortages.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.